CAR⁺ and CAR^- T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies.

ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR⁺ T cells, such as product composition, patients' lymphodepletion, and immune reconstitution, are not well understood. To shed light on this issue, here we conduct a single-cell multi-omics analysis of transcriptional, clonal, and phenotypic profiles from pre- to 1-month post-infusion of CAR⁺ and CAR^- T cells from patients from a CARTELL study (ACTRN12617001579381) who received a donor-derived 4-1BB CAR product targeting CD19. Following infusion, CAR⁺ T cells and CAR^- T cells shows similar differentiation profiles with clonally expanded populations across heterogeneous phenotypes, demonst

SUBMITTER: Louie RHY 

PROVIDER: S-EPMC10682404 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature